Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.35 - $5.17 $179,300 - $394,460
76,298 Added 884.2%
84,927 $229 Million
Q1 2024

May 15, 2024

BUY
$0.59 - $5.13 $5,091 - $44,266
8,629 New
8,629 $44.3 Million

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $12.3M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.